Important Safety Information

This page provides important safety details regarding the prescription treatments referenced on this website, including intended use, potential side effects and risks, considerations for specific populations, and possible drug interactions.

Nexlife encourages you to promptly report any side effect or adverse reaction to your licensed healthcare provider and to the pharmacy that dispensed your medication. You may also report suspected adverse reactions directly to the FDA through MedWatch at 1-800-FDA-1088 or at www.fda.gov/medwatch.

If you are experiencing a medical emergency, call 911 or go to your nearest emergency department.

Withholding or providing inaccurate information about your health and medical history in order to obtain treatment may result in harm, including, in some cases, death. Answer all assessment questions completely and accurately.

Advertising Disclosures

All advertising appearing on nexlife.us is paid for by Nexlife Inc. and is intended to market Nexlife's telehealth and care-coordination services.

Some advertising may feature paid actors, models, or dramatizations. Where an advertisement features an actual Nexlife member, or includes an endorsement or testimonial, that fact will be clearly disclosed, along with whether the individual received any form of compensation.

Individual results vary. No specific outcome is promised or guaranteed, and no claim is made regarding the efficacy of any compounded medication.

Nexlife's Role

Nexlife Inc. is a telehealth and care-coordination platform. Nexlife connects individuals with independent, U.S.-licensed healthcare providers who evaluate whether a treatment discussed on this website may be clinically appropriate. Nexlife may also coordinate prescription fulfillment through independent licensed pharmacies.

Nexlife does not practice medicine and does not provide medical advice. Nexlife does not manufacture, compound, test, label, or dispense any medication, and does not direct pharmacy formulation, labeling, or fulfillment decisions. Nexlife is not a pharmacy and is not a licensed healthcare facility.

Completing an online assessment does not create a provider–patient relationship. That relationship is established only upon clinical review and acceptance by a licensed provider. All prescribing decisions rest solely with the treating provider, who may prescribe, adjust, pause, or decline treatment based on clinical judgment, your medical history, contraindications, and applicable state law.

For further detail, see Nexlife's Terms of Service.

Prescriptions and Medications

Prescription medications require evaluation by a qualified, licensed healthcare provider. Whether a prescription is issued is solely at the provider's discretion. Access to any treatment plan or medication is not assured, and no medication is guaranteed to be prescribed, available, or appropriate for you.

Prescriptions issued through providers affiliated with Nexlife are filled by Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL), and Boudreaux's New Drug Store (Lake Charles, LA), each a U.S.-licensed compounding pharmacy. Pharmacy selection, formulation availability, and fulfillment may vary by state, provider direction, pharmacy operations, and applicable law.

All prescription medications carry potential risks. Please review the safety information below in full and discuss any questions with your provider before starting treatment.

Compounded Medications

In certain circumstances, a licensed provider may prescribe a compounded medication, prepared by a U.S.-licensed compounding pharmacy.

Compounded medications are not approved by the U.S. Food and Drug Administration. They have not been evaluated by the FDA for safety, effectiveness, or quality, and they do not undergo the clinical studies required of FDA-approved commercially available products. Compounded medications may nonetheless be lawfully prescribed and dispensed when a licensed provider determines it is clinically appropriate.

Compounded formulations are prepared on a patient-specific basis and may differ from commercially available products in concentration, excipients, appearance, packaging, and labeling. FDA-approved alternatives to compounded semaglutide and compounded tirzepatide exist. You are encouraged to discuss both FDA-approved and compounded options with your provider, including the differences between them, before deciding on a course of treatment.

Compounded semaglutide is not Ozempic® or Wegovy®. Compounded tirzepatide is not Mounjaro® or Zepbound®.

Important Information About Multi-Dose Vials

Compounded GLP-1 medications are commonly dispensed in multi-dose vials, which require you to measure and draw each dose yourself.

Your dose is prescribed in milligrams (mg) or in milliliters (mL) — not in insulin units. Syringes marked in insulin units are not interchangeable with a dose expressed in milligrams. Serious dosing errors, including overdoses of ten times the intended dose, have occurred when patients measured a dose in insulin units rather than following the instructions provided with their medication.

Before your first injection:

  • Read the written instructions supplied with your medication in full.
  • Confirm with your provider or the dispensing pharmacy exactly how much volume to draw for your prescribed dose, and what syringe to use.
  • If the instructions, the vial label, and what you were told do not agree, do not inject. Contact your provider or the dispensing pharmacy first.

Never change your dose, dosing schedule, or injection technique without first speaking to your provider. If you believe you have injected more than your prescribed dose, contact your provider or seek medical attention immediately.

Never share needles or syringes with anyone. Sharing poses a risk of serious infection.

Before Any Surgery or Procedure

Tell your surgeon, anesthesiologist, and any proceduralist that you are taking a GLP-1 medication, including before endoscopy, colonoscopy, dental procedures under sedation, and any surgery involving anesthesia or deep sedation.

These medications slow the emptying of the stomach. Food may remain in the stomach even after standard fasting periods, which increases the risk of aspiration — food or liquid entering the lungs — during anesthesia or sedation. Your care team may direct you to hold doses or extend your fasting period beforehand. Do not stop or adjust your medication on your own; ask your prescribing provider.

Trademark Notice

Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. Nexlife is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly, or the manufacturer of any brand-name medication. These marks are used only to identify those products and to distinguish them from the compounded medications referenced on this website.

Contact

Questions about Nexlife's services or advertising content may be directed to hello@nexlife.us or +1 (949) 818-8000.

Questions about your treatment, your medication, or a side effect should be directed to your treating provider or the dispensing pharmacy, not to Nexlife.

Compounded Semaglutide

Important Safety Information Regarding Compounded Semaglutide

Compounded semaglutide is not FDA-approved. It has not been evaluated by the FDA for safety, effectiveness, or quality, and it has not undergone the clinical studies required of commercially available FDA-approved products. A compounded product may still be lawfully prescribed, and your provider may issue a prescription for compounded semaglutide following your medical consultation. Compounded semaglutide is not Ozempic® or Wegovy®. FDA-approved alternatives exist; ask your provider about them.

The information below describes risks associated with semaglutide as an active ingredient, drawn from the labeling of FDA-approved semaglutide products. Because compounded formulations are not FDA-approved and have not been studied, their risk profile may differ, and additional risks may exist that are not described here.

What semaglutide is

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. In its FDA-approved form it is indicated, in combination with a reduced-calorie diet and increased physical activity, for chronic weight management in adults with an initial body mass index (BMI) of:

  • 30 kg/m² or greater (obesity), or
  • 27 kg/m² or greater (overweight) with at least one weight-related comorbid condition, such as hypertension, type 2 diabetes mellitus, or dyslipidemia.

Speak with your healthcare provider about whether semaglutide may be appropriate for you.

WARNING: RISK OF THYROID C-CELL TUMORS

In studies in rodents, semaglutide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors, including thyroid cancer. It is not known whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans.

Tell your healthcare provider right away if you develop a lump or swelling in your neck, hoarseness, difficulty swallowing, or shortness of breath. These may be symptoms of thyroid cancer.

Who should not use semaglutide

Do not use semaglutide if:

  • You or any family member has ever had medullary thyroid carcinoma (MTC).
  • You have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • You have had a serious hypersensitivity reaction to semaglutide or to any component of the formulation.

Before starting semaglutide

Tell your healthcare provider about all of your medical conditions, including if you:

  • Have or have had problems with your pancreas or your kidneys.
  • Have or have had gallbladder disease or gallstones.
  • Have severe problems with your stomach, such as slowed stomach emptying (gastroparesis) or problems digesting food.
  • Have type 2 diabetes, particularly with a history of diabetic retinopathy.
  • Have or have had depression, suicidal thoughts, or other mental health conditions.
  • Have a history of eye disease affecting the optic nerve.
  • Are pregnant or plan to become pregnant. Semaglutide should not be used during pregnancy, and there may be risks to an unborn baby from exposure during pregnancy. Discuss with your provider; FDA-approved labeling advises discontinuing semaglutide at least 2 months before a planned pregnancy.
  • Are breastfeeding or plan to breastfeed. It is not known whether semaglutide passes into human breast milk.
  • Have any scheduled surgery or procedure involving anesthesia or sedation.

Tell your provider about all medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Semaglutide may affect how some medicines work, and some medicines may affect how semaglutide works. This is particularly important if you take insulin or a sulfonylurea, or any medication that requires close monitoring.

Because semaglutide slows gastric emptying, it may affect the absorption of oral medications taken at the same time. Discuss the timing of your other medications with your provider.

Serious side effects

You or a caregiver should monitor carefully for the following, especially when starting treatment and after any dose change. Semaglutide may cause serious side effects, including:

Thyroid C-cell tumors. Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. See the boxed warning above.

Inflammation of the pancreas (pancreatitis). Stop using semaglutide and contact your provider immediately if you have severe, persistent pain in your abdomen, with or without vomiting, that may radiate to your back.

Gallbladder problems. Semaglutide may cause gallbladder problems, including gallstones. Some cases require surgery. Contact your provider if you have pain in your upper abdomen, fever, yellowing of the skin or eyes (jaundice), or clay-colored stools.

Low blood sugar (hypoglycemia). Your risk is higher if you use semaglutide with insulin or a sulfonylurea. Signs may include dizziness or light-headedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, or feeling jittery. Talk with your provider about how to recognize and treat low blood sugar, and about monitoring your blood sugar before and during treatment.

Kidney problems, including kidney failure. Nausea, vomiting, and diarrhea can cause dehydration, which may worsen existing kidney problems or cause new ones. Drink fluids to reduce the risk of dehydration, and contact your provider if you cannot keep fluids down.

Slowed stomach emptying (gastroparesis). Symptoms may include feeling full shortly after starting a meal, feeling full long after eating, nausea, and vomiting. Contact your provider if you experience these.

Increased risk of aspiration during anesthesia or deep sedation. Because these medications slow stomach emptying, food may remain in the stomach despite standard fasting. Tell every member of your surgical, dental, or procedural care team that you take a GLP-1 medication.

Serious allergic reactions. Stop using semaglutide and seek medical attention immediately if you have swelling of your face, lips, tongue, or throat; trouble breathing or swallowing; severe rash or itching; fainting or dizziness; or a very rapid heartbeat.

Changes in vision. Tell your provider about any change in vision. In people with type 2 diabetes and a history of diabetic retinopathy, rapid improvement in blood glucose has been associated with temporary worsening of retinopathy.

Non-arteritic anterior ischemic optic neuropathy (NAION). Cases of NAION, a condition involving sudden loss of vision in one eye due to reduced blood flow to the optic nerve, have been reported in patients taking semaglutide. Seek medical attention promptly for any sudden change or loss of vision.

Increased heart rate. Semaglutide may increase your resting heart rate. Tell your provider if you feel your heart racing or pounding.

Depression or thoughts of suicide. Pay attention to any changes in mood, behavior, thoughts, or feelings, particularly sudden changes. Contact your provider immediately if you experience mental health changes that are new, worse, or concerning to you.

Common side effects

The most common side effects of semaglutide may include: nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, indigestion, dizziness, abdominal bloating, belching, gas, gastroenteritis, gastroesophageal reflux, and injection-site reactions.

These are not all of the possible side effects. Talk to your provider about any side effect that bothers you or does not go away.

How semaglutide is taken

Semaglutide may be taken with or without food. It is self-administered as a subcutaneous injection in the abdomen, thigh, or upper arm, once weekly on the same day each week.

Your provider will direct your dosing regimen, including any dose escalation schedule. Do not change your dose or dosing schedule, and do not stop treatment, without first discussing it with your provider.

If your medication is supplied in a multi-dose vial, read the section on multi-dose vials above before your first injection. Doses are prescribed in milligrams or milliliters, not in insulin units.

Never share needles or syringes with anyone. Sharing poses a risk of serious infection.

Stopping treatment

Weight regain is common after discontinuing GLP-1 treatment. Discuss any plan to stop treatment with your provider.

Reporting side effects

Report side effects to your provider and to the dispensing pharmacy. You are also encouraged to report them to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

This information is not comprehensive. Please discuss any questions or concerns about semaglutide with your healthcare provider.

Compounded Tirzepatide

Important Safety Information Regarding Compounded Tirzepatide

Compounded tirzepatide is not FDA-approved. It has not been evaluated by the FDA for safety, effectiveness, or quality, and it has not undergone the clinical studies required of commercially available FDA-approved products. A compounded product may still be lawfully prescribed, and your provider may issue a prescription for compounded tirzepatide following your medical consultation. Compounded tirzepatide is not Mounjaro® or Zepbound®. FDA-approved alternatives exist; ask your provider about them.

The information below describes risks associated with tirzepatide as an active ingredient, drawn from the labeling of FDA-approved tirzepatide products. Because compounded formulations are not FDA-approved and have not been studied, their risk profile may differ, and additional risks may exist that are not described here.

What tirzepatide is

Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. In its FDA-approved form it is indicated, in combination with a reduced-calorie diet and increased physical activity, for chronic weight management in adults with an initial body mass index (BMI) of:

  • 30 kg/m² or greater (obesity), or
  • 27 kg/m² or greater (overweight) with at least one weight-related comorbid condition, such as hypertension, type 2 diabetes mellitus, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.

Speak with your healthcare provider about whether tirzepatide may be appropriate for you.

WARNING: RISK OF THYROID C-CELL TUMORS

In studies in rodents, tirzepatide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors. It is not known whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans.

Tell your healthcare provider right away if you develop a lump or swelling in your neck, hoarseness, difficulty swallowing, or shortness of breath. These may be symptoms of thyroid cancer.

Who should not use tirzepatide

Do not use tirzepatide if:

  • You or any family member has ever had medullary thyroid carcinoma (MTC).
  • You have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • You have had a serious hypersensitivity reaction to tirzepatide or to any component of the formulation.

Before starting tirzepatide

Tell your healthcare provider about all of your medical conditions, including if you:

  • Have or have had problems with your pancreas or your kidneys.
  • Have or have had gallbladder disease or gallstones.
  • Have severe gastrointestinal disease, including severe gastroparesis or other problems digesting food. Tirzepatide has not been studied in patients with severe gastrointestinal disease and is not recommended in these patients.
  • Have a history of diabetic retinopathy.
  • Have or have had depression, suicidal thoughts, or other mental health conditions.
  • Are pregnant or plan to become pregnant. Tirzepatide should not be used during pregnancy, and there may be risks to an unborn baby from exposure during pregnancy. Discuss with your provider whether and how to stop tirzepatide before a planned pregnancy.
  • Are breastfeeding or plan to breastfeed. It is not known whether tirzepatide passes into human breast milk.
  • Have any scheduled surgery or procedure involving anesthesia or sedation.

If you use oral hormonal birth control: Tirzepatide may reduce its effectiveness by delaying gastric emptying. FDA-approved labeling advises switching to a non-oral contraceptive method, or adding a barrier method of contraception, for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase, until you reach your maintenance dose. Discuss this with your provider before starting treatment.

Tell your provider about all medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Tirzepatide may affect how some medicines work, and some medicines may affect how tirzepatide works. Tell your provider if you take insulin or a sulfonylurea, as tirzepatide may increase your risk of low blood sugar.

Because tirzepatide slows gastric emptying, it may affect the absorption of oral medications taken at the same time. Discuss the timing of your other medications with your provider.

Serious side effects

You or a caregiver should monitor carefully for the following, especially when starting treatment and after any dose change. Tirzepatide may cause serious side effects, including:

Thyroid C-cell tumors. Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. See the boxed warning above.

Inflammation of the pancreas (pancreatitis). Stop using tirzepatide and contact your provider immediately if you have severe, persistent pain in your abdomen, with or without vomiting, that may radiate to your back.

Gallbladder problems. Tirzepatide may cause gallbladder problems, including gallstones. Some cases require surgery. Contact your provider if you have pain in your upper abdomen, fever, yellowing of the skin or eyes (jaundice), or clay-colored stools.

Low blood sugar (hypoglycemia). Your risk is higher if you use tirzepatide with insulin or a sulfonylurea. Signs may include dizziness or light-headedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, or feeling jittery. Talk with your provider about how to recognize and treat low blood sugar, and about monitoring your blood sugar before and during treatment.

Kidney problems, including kidney failure. Nausea, vomiting, and diarrhea can cause dehydration, which may worsen existing kidney problems or cause new ones. Drink fluids to reduce the risk of dehydration, and contact your provider if you cannot keep fluids down.

Slowed stomach emptying (gastroparesis). Symptoms may include feeling full shortly after starting a meal, feeling full long after eating, nausea, and vomiting. Contact your provider if you experience these.

Increased risk of aspiration during anesthesia or deep sedation. Because these medications slow stomach emptying, food may remain in the stomach despite standard fasting. Tell every member of your surgical, dental, or procedural care team that you take a GLP-1 medication.

Serious allergic reactions. Stop using tirzepatide and seek medical attention immediately if you have swelling of your face, lips, tongue, or throat; trouble breathing or swallowing; severe rash or itching; fainting or dizziness; or a very rapid heartbeat.

Changes in vision. Tell your provider about any change in vision. In people with type 2 diabetes and a history of diabetic retinopathy, rapid improvement in blood glucose has been associated with temporary worsening of retinopathy.

Depression or thoughts of suicide. Pay attention to any changes in mood, behavior, thoughts, or feelings, particularly sudden changes. Contact your provider immediately if you experience mental health changes that are new, worse, or concerning to you.

Common side effects

The most common side effects of tirzepatide may include: nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection-site reactions, fatigue, hypersensitivity reactions, belching, hair loss, and heartburn.

These are not all of the possible side effects. Talk to your provider about any side effect that bothers you or does not go away.

How tirzepatide is taken

Tirzepatide may be taken with or without food. It is self-administered as a subcutaneous injection in the abdomen, thigh, or upper arm, once weekly on the same day each week.

Your provider will direct your dosing regimen, including any dose escalation schedule. Do not change your dose or dosing schedule, and do not stop treatment, without first discussing it with your provider.

If your medication is supplied in a multi-dose vial, read the section on multi-dose vials above before your first injection. Doses are prescribed in milligrams or milliliters, not in insulin units.

Never share needles or syringes with anyone. Sharing poses a risk of serious infection.

Stopping treatment

Weight regain is common after discontinuing GLP-1 treatment. Discuss any plan to stop treatment with your provider.

Reporting side effects

Report side effects to your provider and to the dispensing pharmacy. You are also encouraged to report them to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

This information is not comprehensive. Please discuss any questions or concerns about tirzepatide with your healthcare provider.

Sermorelin Injection

Important Safety Information Regarding Compounded Sermorelin

Compounded sermorelin is not approved by the U.S. Food and Drug Administration. It has not been evaluated by the FDA for safety, effectiveness, or quality. There is no FDA-approved sermorelin product currently marketed in the United States. The information below is drawn from pharmacology, historical product information, and published reports rather than from current FDA-approved labeling, and it is therefore less complete than the information available for approved medicines.

A compounded product may be lawfully prescribed in appropriate circumstances, and your provider may issue a prescription for compounded sermorelin following your medical consultation.

What sermorelin is

Sermorelin is a synthetic analogue of growth hormone–releasing hormone (GHRH). It acts on the pituitary gland to stimulate the body's own release of growth hormone.

Sermorelin has not been shown in adequate and well-controlled studies to slow aging, improve body composition, increase strength, improve sleep, or produce any of the outcomes with which growth hormone secretagogues are often associated in marketing. Any use for these purposes is not established, and outcomes are not predictable.

Speak with your healthcare provider about whether sermorelin may be appropriate for you, and about what is and is not known regarding its effects.

Who should not use sermorelin

Do not use sermorelin if:

  • You are allergic to sermorelin or to any component of the formulation.
  • You have an active malignancy, or a history of cancer that has not been cleared by your treating oncologist. Growth hormone has the potential to stimulate the growth of existing tumors.
  • You are pregnant, plan to become pregnant, or are breastfeeding.

Before starting sermorelin

Tell your healthcare provider about all of your medical conditions, including if you:

  • Have or have had any form of cancer, or have a family history of cancer.
  • Have diabetes, prediabetes, or impaired glucose tolerance. Growth hormone can raise blood glucose and reduce insulin sensitivity.
  • Have thyroid disease or untreated hypothyroidism, which can blunt the response to sermorelin and may require treatment first.
  • Have any disorder of the pituitary or hypothalamus, or have had surgery or radiation involving these areas.
  • Have intracranial hypertension, severe headaches, or vision changes.
  • Have carpal tunnel syndrome or other nerve compression conditions.
  • Have heart, liver, or kidney disease.
  • Have obstructive sleep apnea.
  • Take corticosteroids, thyroid hormone, insulin, or any medication affecting blood glucose.

Tell your provider about all medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Medicines that suppress growth hormone secretion, including corticosteroids, may reduce or eliminate any effect of sermorelin.

Serious side effects

Serious allergic reactions. Stop using sermorelin and seek immediate medical attention if you have swelling of the face, lips, tongue, or throat; trouble breathing or swallowing; severe rash or hives; fainting or dizziness; or a very rapid heartbeat.

Elevated blood glucose and reduced insulin sensitivity. Growth hormone can raise blood sugar. If you have diabetes or prediabetes, your provider should monitor your glucose and may need to adjust other medications.

Effects on existing tumors. Growth hormone can promote the growth of some tumors. Report any new lump, unexplained weight loss, or persistent symptom to your provider.

Increased intracranial pressure. Contact your provider promptly for severe or persistent headache, nausea and vomiting, or changes in vision.

Fluid retention. May cause swelling in the hands, feet, or ankles, joint pain, or muscle pain. Report persistent swelling or pain.

Carpal tunnel symptoms. Numbness, tingling, or pain in the hands or wrists should be reported to your provider.

Worsening of sleep apnea. Report new or worsening snoring, witnessed pauses in breathing, or daytime sleepiness.

Common side effects

Pain, redness, itching, or swelling at the injection site; flushing; headache; dizziness or light-headedness; difficulty swallowing; fatigue; restlessness; and altered taste. Talk to your provider about any side effect that bothers you or does not go away.

Monitoring

Your provider may recommend periodic monitoring of growth hormone or IGF-1 levels, blood glucose, thyroid function, and general health during treatment. Follow the monitoring schedule your provider sets.

How sermorelin is taken

Sermorelin is self-administered as a subcutaneous injection, typically at bedtime, on the schedule your provider directs. Use aseptic technique, inject slowly, and rotate injection sites.

If your medication is supplied in a multi-dose vial, confirm exactly what volume to draw and what syringe to use before your first injection. Do not change your dose or schedule, and do not stop treatment, without speaking to your provider first.

Never share needles or syringes with anyone. Sharing poses a risk of serious infection.

Reporting side effects

Report side effects to your provider and to the dispensing pharmacy. You are also encouraged to report them to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

This information is not comprehensive, and less is known about compounded sermorelin than about FDA-approved medicines. Discuss any questions or concerns with your healthcare provider.

NAD+ Injection

Important Safety Information Regarding Compounded NAD+

Compounded NAD+ injection is not approved by the U.S. Food and Drug Administration. It has not been evaluated by the FDA for safety, effectiveness, or quality. There is no FDA-approved NAD+ injectable product. The information below is drawn from pharmacology and published reports rather than from FDA-approved labeling, and it is less complete than the information available for approved medicines.

What NAD+ is

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in all human cells and involved in cellular energy metabolism and repair processes.

Injectable NAD+ has not been shown in adequate and well-controlled clinical trials to treat, prevent, or improve any condition. Claims regarding energy, cognition, aging, addiction recovery, athletic performance, or longevity are not established. Speak with your provider about what is and is not known.

Who should not use NAD+ injection

Do not use NAD+ injection if:

  • You are allergic to NAD+ or to any component of the formulation.
  • You are pregnant, plan to become pregnant, or are breastfeeding. Effects on pregnancy and on a nursing infant are unknown.

Before starting NAD+ injection

Tell your healthcare provider about all of your medical conditions, including if you:

  • Have any autoimmune, metabolic, liver, or kidney condition.
  • Have a history of gout or elevated uric acid.
  • Have a history of cardiac arrhythmia or blood pressure instability.
  • Have any active infection or malignancy.
  • Take any prescription or over-the-counter medication, vitamin, or herbal supplement.

No comprehensive drug interaction data exists for injectable NAD+. The absence of reported interactions reflects the absence of study, not established safety. Give your provider your complete medication and supplement list.

Serious side effects

Serious allergic reactions. Stop using and seek immediate medical attention for swelling of the face, lips, tongue, or throat; trouble breathing; severe rash or hives; fainting; or a very rapid heartbeat.

Cardiovascular effects. Rapid administration has been associated with chest tightness, palpitations, changes in blood pressure, and shortness of breath. Inject slowly as directed and stop if these occur.

Injection-site infection. Any injection carries a risk of infection. Contact your provider for spreading redness, warmth, swelling, drainage, or fever.

Common side effects

Redness, tenderness, or soreness at the injection site; warmth or flushing; light-headedness; nausea; headache; and transient fatigue.

How NAD+ is taken

Administered by subcutaneous injection on the schedule and at the dose your provider directs. Inject slowly over 20–30 seconds and rotate injection sites. Do not exceed the volume per injection your provider specifies. Do not change your dose or schedule without speaking to your provider.

Never share needles or syringes with anyone. Sharing poses a risk of serious infection.

Reporting side effects

Report side effects to your provider and to the dispensing pharmacy, and to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

This information is not comprehensive, and substantially less is known about injectable NAD+ than about FDA-approved medicines.

Glutathione Injection

Important Safety Information Regarding Compounded Glutathione

Compounded glutathione injection is not approved by the U.S. Food and Drug Administration. It has not been evaluated by the FDA for any medical use, dose, or safety profile, and its safety and effectiveness for any condition are not established. There is no FDA-approved injectable glutathione product. If you would prefer an FDA-approved treatment, ask your provider about alternatives.

What glutathione is

Glutathione is a naturally occurring tripeptide (glutamate, cysteine, glycine) that functions as an antioxidant within cells.

Injectable glutathione has not been shown in adequate and well-controlled clinical trials to treat, prevent, or improve any condition. Speak with your provider about what is and is not known.

Who should not use glutathione injection

Do not use glutathione injection if:

  • You are allergic to glutathione or to any component of the formulation.
  • You have glucose-6-phosphate dehydrogenase (G6PD) deficiency. Glutathione may trigger destruction of red blood cells (hemolytic anemia) in people with this condition.
  • You have uncontrolled asthma, or have previously experienced bronchospasm associated with glutathione.
  • You are pregnant, plan to become pregnant, or are breastfeeding, unless specifically directed by your provider.
  • You have an active infection, fever, or active malignancy, unless cleared by the treating specialist.

Before starting glutathione injection

Tell your healthcare provider about all of your medical conditions, including if you:

  • Have or have had liver or kidney disease.
  • Have asthma, COPD, or any chronic lung condition.
  • Have a personal or family history of G6PD deficiency, unexplained anemia, or episodes of jaundice.
  • Are receiving chemotherapy or any other antioxidant therapy. Antioxidants may interact with some cancer treatments; discuss with your oncologist before use.
  • Take any prescription or over-the-counter medication, vitamin, or herbal supplement.

Serious side effects

Serious allergic reactions, including anaphylaxis. Stop using and seek emergency care for swelling of the face, lips, tongue, or throat; difficulty breathing; rash or hives; fainting; or a very rapid heartbeat.

Bronchospasm or worsening asthma. Stop using and contact your provider for wheezing, chest tightness, or shortness of breath.

Hemolytic anemia in people with G6PD deficiency. Seek medical attention for unusual fatigue, pallor, dark urine, or yellowing of the skin or eyes.

Skin reactions. Serious skin reactions, including Stevens-Johnson syndrome, have been reported with injectable glutathione. Stop using and seek immediate medical attention for widespread rash, blistering, peeling skin, or sores in the mouth, eyes, or genitals.

Injection-site infection. Contact your provider for spreading redness, warmth, swelling, drainage, or fever.

Common side effects

Injection-site pain, redness, or swelling; headache; light-headedness; flushing; mild nausea; abdominal discomfort; diarrhea; fatigue.

How glutathione is taken

Administered by subcutaneous or intramuscular injection at the dose and frequency your provider directs. Use aseptic technique, inject slowly over approximately 20–30 seconds, and rotate injection sites. Do not change your dose or schedule, and do not stop treatment, without speaking to your provider.

Never share needles or syringes with anyone. Sharing poses a risk of serious infection.

Reporting side effects

Report side effects to your provider and to the dispensing pharmacy, and to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

This information is not comprehensive, and substantially less is known about injectable glutathione than about FDA-approved medicines.

Lipo-C Injection

Important Safety Information Regarding Compounded Lipo-C

Compounded Lipo-C is not approved by the U.S. Food and Drug Administration and has not been evaluated for safety, effectiveness, or quality. There is no FDA-approved Lipo-C product. The information below is drawn from the known properties of the individual components rather than from FDA-approved labeling for the combination.

What Lipo-C is

Lipo-C, sometimes called an MIC injection, is a lipotropic formulation that typically contains methionine, inositol, choline, and pyridoxine (vitamin B6). Exact composition and concentration vary by compounding pharmacy — ask your pharmacy for the specific formulation you have been prescribed.

Lipotropic injections have not been shown in adequate and well-controlled clinical trials to cause weight loss or to improve body composition. Any weight change during a program that includes these injections is likely attributable to diet, activity, and other treatments. Speak with your provider about what is and is not known.

Who should not use Lipo-C

Do not use Lipo-C if:

  • You are allergic to methionine, inositol, choline, any B vitamin, or any component of the formulation.
  • You have a history of Leber's hereditary optic neuropathy or other hereditary optic nerve disorder.
  • You have severe liver disease, chronic kidney disease, or active peptic ulcer disease.
  • You are pregnant, plan to become pregnant, or are breastfeeding.

Before starting Lipo-C

Tell your healthcare provider about all of your medical conditions, including if you:

  • Have or have had liver or kidney problems.
  • Have cardiovascular disease, high cholesterol, or elevated homocysteine.
  • Have gout, high uric acid, or a history of kidney stones.
  • Have pernicious anemia, folate deficiency, or vitamin B12 deficiency.
  • Have peripheral neuropathy or any nerve or sensory disorder.
  • Have any eye or optic nerve condition.
  • Take levodopa. High-dose pyridoxine can reduce its effectiveness unless it is combined with carbidopa.
  • Take any prescription or over-the-counter medication, vitamin, or herbal supplement. Tell your provider about any other product containing B vitamins, so that combined intake can be assessed.

Serious side effects

Serious allergic reactions, including anaphylaxis. Seek emergency care for swelling of the face, lips, tongue, or throat; difficulty breathing; rash; or a very rapid heartbeat.

Optic nerve damage in people with hereditary optic neuropathy.

Peripheral neuropathy with prolonged or high-dose pyridoxine (B6). Report numbness, tingling, burning, or loss of sensation in the hands or feet, and unsteadiness when walking. This can become irreversible if not addressed early.

Elevated homocysteine, which may increase cardiovascular risk in susceptible individuals.

Worsening gout or elevated uric acid. Report joint pain and swelling.

Injection-site infection. Contact your provider for spreading redness, warmth, swelling, drainage, or fever.

Common side effects

Injection-site redness, swelling, or soreness; mild nausea or upset stomach; headache; dizziness; body odor or fishy breath (associated with choline); fatigue.

How Lipo-C is taken

Self-administered by subcutaneous or intramuscular injection in the abdomen, thigh, or upper arm, at the frequency your provider directs. Inject slowly over 20–30 seconds and rotate injection sites. Do not exceed the volume per injection your provider specifies. Do not change your dose or schedule without speaking to your provider.

Never share needles or syringes with anyone. Sharing poses a risk of serious infection.

Reporting side effects

Report side effects to your provider and to the dispensing pharmacy, and to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

This information is not comprehensive. Discuss any questions or concerns with your healthcare provider.

Lipo-B Injection

Important Safety Information Regarding Compounded Lipo-B

Compounded Lipo-B is not approved by the U.S. Food and Drug Administration and has not been evaluated for safety, effectiveness, or quality. There is no FDA-approved Lipo-B product. The information below is drawn from the known properties of the individual components rather than from FDA-approved labeling for the combination.

What Lipo-B is

Lipo-B is an injectable B-vitamin formulation that commonly contains cyanocobalamin (B12), thiamine (B1), riboflavin (B2), niacinamide (B3), pyridoxine (B6), and dexpanthenol (B5). Some pharmacies include additional components such as L-carnitine or inositol. Composition and concentration vary — ask your pharmacy for the specific formulation you have been prescribed.

B-vitamin injections have not been shown in adequate and well-controlled clinical trials to cause weight loss or to increase energy in people who are not deficient. If you have a diagnosed deficiency, discuss with your provider whether treatment is appropriate and how it should be monitored.

Who should not use Lipo-B

Do not use Lipo-B if:

  • You are allergic to any B vitamin or to any component of the formulation, including cobalt.
  • You have a history of Leber's hereditary optic neuropathy. High-dose B12 may precipitate optic atrophy in this condition.
  • You have severe liver disease or active peptic ulcer disease, unless cleared by your provider.
  • You are pregnant, plan to become pregnant, or are breastfeeding, unless your provider determines the benefits outweigh the risks.

Before starting Lipo-B

Tell your healthcare provider about all of your medical conditions, including if you:

  • Have or have had liver or kidney problems.
  • Have cardiovascular disease, elevated homocysteine, or gout.
  • Have peripheral neuropathy or any nerve or sensory disorder.
  • Have any eye or optic nerve condition.
  • Have a history of anemia. B12 supplementation can mask the blood findings of vitamin B12 deficiency while neurological damage continues; tell your provider if anemia or B12 deficiency has ever been suspected.
  • Take levodopa (efficacy may be reduced by high-dose pyridoxine unless combined with carbidopa), phenytoin or phenobarbital (B vitamins can alter serum levels; monitoring may be required), or drink alcohol regularly (chronic use impairs B-vitamin absorption and increases liver risk).
  • Take any other prescription or over-the-counter medication, vitamin, or herbal supplement, including any other product containing B vitamins.

Serious side effects

Serious allergic reactions, including anaphylaxis. Seek emergency care for swelling of the face, lips, tongue, or throat; difficulty breathing; rash; or a very rapid heartbeat.

Optic nerve damage in people with hereditary optic neuropathy.

Peripheral neuropathy with prolonged or high-dose pyridoxine (B6). Report numbness, tingling, burning, or loss of sensation in the hands or feet, and unsteadiness when walking. This can become irreversible if not addressed early.

Liver effects or significant flushing with large niacinamide doses. Report yellowing of the skin or eyes, dark urine, or persistent severe flushing.

Masking of B12 deficiency. Supplementation can normalize blood counts while neurological damage from an underlying deficiency progresses. Report numbness, memory changes, or balance problems.

Injection-site infection. Contact your provider for spreading redness, warmth, swelling, drainage, or fever.

Common side effects

Injection-site redness, swelling, or soreness; mild flushing or warmth; nausea; headache; dizziness; fatigue; transient diarrhea or upset stomach.

How Lipo-B is taken

Self-administered by subcutaneous or intramuscular injection in the abdomen, thigh, or upper arm, typically once weekly or as your provider directs. Inject slowly over 20–30 seconds and rotate injection sites. Do not exceed the volume per injection your provider specifies. Do not change your dose or schedule without speaking to your provider.

Never share needles or syringes with anyone. Sharing poses a risk of serious infection.

Reporting side effects

Report side effects to your provider and to the dispensing pharmacy, and to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

This information is not comprehensive. Discuss any questions or concerns with your healthcare provider.